CN106188205B - A kind of purposes of momordica grosvenori alcohol derivatives monomer and combinations thereof - Google Patents
A kind of purposes of momordica grosvenori alcohol derivatives monomer and combinations thereof Download PDFInfo
- Publication number
- CN106188205B CN106188205B CN201610520359.0A CN201610520359A CN106188205B CN 106188205 B CN106188205 B CN 106188205B CN 201610520359 A CN201610520359 A CN 201610520359A CN 106188205 B CN106188205 B CN 106188205B
- Authority
- CN
- China
- Prior art keywords
- cancer
- momordica grosvenori
- alcohol derivatives
- derivatives monomer
- grosvenori alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000011171 Thladiantha grosvenorii Nutrition 0.000 title claims abstract description 69
- 239000000178 monomer Substances 0.000 title claims abstract description 69
- 150000001298 alcohols Chemical class 0.000 title claims abstract description 57
- 241001409321 Siraitia grosvenorii Species 0.000 title claims abstract 10
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 81
- 239000003814 drug Substances 0.000 claims abstract description 45
- 201000011510 cancer Diseases 0.000 claims abstract description 37
- 239000000203 mixture Substances 0.000 claims abstract description 34
- -1 triterpene glucoside Chemical class 0.000 claims abstract description 15
- 230000036541 health Effects 0.000 claims abstract description 13
- 230000033228 biological regulation Effects 0.000 claims abstract description 8
- 230000001900 immune effect Effects 0.000 claims abstract description 6
- 230000004089 microcirculation Effects 0.000 claims abstract description 5
- 210000004027 cell Anatomy 0.000 claims description 34
- 239000000243 solution Substances 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 12
- 206010025323 Lymphomas Diseases 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 10
- 210000002751 lymph Anatomy 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 239000000839 emulsion Substances 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- 239000006187 pill Substances 0.000 claims description 5
- 239000000829 suppository Substances 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 230000000699 topical effect Effects 0.000 claims description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 206010003571 Astrocytoma Diseases 0.000 claims description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims description 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 4
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 4
- 208000032612 Glial tumor Diseases 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 201000010208 Seminoma Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- 201000001531 bladder carcinoma Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 201000010175 gallbladder cancer Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 210000004324 lymphatic system Anatomy 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 201000008968 osteosarcoma Diseases 0.000 claims description 4
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 4
- 239000000049 pigment Substances 0.000 claims description 4
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 208000001608 teratocarcinoma Diseases 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- 210000001685 thyroid gland Anatomy 0.000 claims description 4
- 208000010570 urinary bladder carcinoma Diseases 0.000 claims description 4
- 241000792859 Enema Species 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 3
- 239000008298 dragée Substances 0.000 claims description 3
- 239000007920 enema Substances 0.000 claims description 3
- 229940095399 enema Drugs 0.000 claims description 3
- 239000000865 liniment Substances 0.000 claims description 3
- 229940040145 liniment Drugs 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 239000006072 paste Substances 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 239000007940 sugar coated tablet Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 18
- 229930012538 Paclitaxel Natural products 0.000 abstract description 7
- 229960001592 paclitaxel Drugs 0.000 abstract description 7
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract description 7
- 229930182478 glucoside Natural products 0.000 abstract description 6
- 230000000259 anti-tumor effect Effects 0.000 abstract description 4
- 239000002246 antineoplastic agent Substances 0.000 abstract description 2
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 2
- 230000006872 improvement Effects 0.000 abstract description 2
- 238000001228 spectrum Methods 0.000 abstract 1
- 244000185386 Thladiantha grosvenorii Species 0.000 description 59
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 56
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- 150000001875 compounds Chemical class 0.000 description 25
- 239000000284 extract Substances 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 229940079593 drug Drugs 0.000 description 19
- 239000007787 solid Substances 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 14
- 238000004128 high performance liquid chromatography Methods 0.000 description 14
- 238000000926 separation method Methods 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- 239000000741 silica gel Substances 0.000 description 12
- 229910002027 silica gel Inorganic materials 0.000 description 12
- 229960001866 silicon dioxide Drugs 0.000 description 12
- 238000010828 elution Methods 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 8
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 7
- 235000013399 edible fruits Nutrition 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 229930182470 glycoside Natural products 0.000 description 6
- 150000002338 glycosides Chemical class 0.000 description 6
- JLYBBRAAICDTIS-AYEHCKLZSA-N mogrol Chemical compound C([C@H]1[C@]2(C)CC[C@@H]([C@]2(C[C@@H](O)[C@]11C)C)[C@@H](CC[C@@H](O)C(C)(C)O)C)C=C2[C@H]1CC[C@H](O)C2(C)C JLYBBRAAICDTIS-AYEHCKLZSA-N 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 5
- 229930182494 ginsenoside Natural products 0.000 description 5
- 229940089161 ginsenoside Drugs 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- GHBNZZJYBXQAHG-KUVSNLSMSA-N (2r,3r,4s,5s,6r)-2-[[(2r,3s,4s,5r,6r)-6-[[(3s,8s,9r,10r,11r,13r,14s,17r)-17-[(2r,5r)-5-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-3-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@H](CC[C@@H](C)[C@@H]1[C@]2(C[C@@H](O)[C@@]3(C)[C@H]4C(C([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]6[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O6)O)O5)O)CC4)(C)C)=CC[C@H]3[C@]2(C)CC1)C)C(C)(C)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GHBNZZJYBXQAHG-KUVSNLSMSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 235000008504 concentrate Nutrition 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000003810 ethyl acetate extraction Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 150000008131 glucosides Chemical class 0.000 description 4
- TVJXHJAWHUMLLG-UHFFFAOYSA-N mogroside V Natural products CC(CCC(OC1OC(COC2OC(CO)C(O)C(O)C2OC3OC(CO)C(O)C(O)C3O)C(O)C(O)C1O)C(C)(C)O)C4CCC5(C)C6CC=C7C(CCC(OC8OC(COC9OC(CO)C(O)C(O)C9O)C(O)C(O)C8O)C7(C)C)C6(C)C(O)CC45C TVJXHJAWHUMLLG-UHFFFAOYSA-N 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000651 prodrug Chemical group 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 210000000664 rectum Anatomy 0.000 description 4
- 239000007909 solid dosage form Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 235000009815 Momordica Nutrition 0.000 description 3
- 241000218984 Momordica Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- 238000001815 biotherapy Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- JLYBBRAAICDTIS-UHFFFAOYSA-N mogrol Natural products CC12C(O)CC3(C)C(C(CCC(O)C(C)(C)O)C)CCC3(C)C1CC=C1C2CCC(O)C1(C)C JLYBBRAAICDTIS-UHFFFAOYSA-N 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229920002732 Polyanhydride Polymers 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000005906 dihydroxylation reaction Methods 0.000 description 2
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000000505 pernicious effect Effects 0.000 description 2
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- NWMIYTWHUDFRPL-UHFFFAOYSA-N sapogenin Natural products COC(=O)C1(CO)C(O)CCC2(C)C1CCC3(C)C2CC=C4C5C(C)(O)C(C)CCC5(CCC34C)C(=O)O NWMIYTWHUDFRPL-UHFFFAOYSA-N 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- KBIWNQVZKHSHTI-UHFFFAOYSA-N 4-n,4-n-dimethylbenzene-1,4-diamine;oxalic acid Chemical compound OC(=O)C(O)=O.CN(C)C1=CC=C(N)C=C1 KBIWNQVZKHSHTI-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 240000009087 Crescentia cujete Species 0.000 description 1
- 235000005983 Crescentia cujete Nutrition 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- DORPKYRPJIIARM-UHFFFAOYSA-N Decaffeoylacteoside Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(OCCC=2C=C(O)C(O)=CC=2)OC(CO)C1O DORPKYRPJIIARM-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 235000009797 Lagenaria vulgaris Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Natural products OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 241000220324 Pyrus Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- DORPKYRPJIIARM-GYAWPQPFSA-N Verbasoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](OCCC=2C=C(O)C(O)=CC=2)O[C@H](CO)[C@H]1O DORPKYRPJIIARM-GYAWPQPFSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000007046 ethoxylation reaction Methods 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 239000007887 hard shell capsule Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 230000009215 host defense mechanism Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000010832 independent-sample T-test Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000006101 laboratory sample Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229930189775 mogroside Natural products 0.000 description 1
- 229930191873 mogroside II Natural products 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 229940041678 oral spray Drugs 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000021017 pears Nutrition 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000011257 shell material Substances 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a kind of purposes of momordica grosvenori alcohol derivatives monomer (4) in for treatment and/or pre- preventing tumor and/or the medicine of cancer, and the purposes in for immunological regulation, improvement microcirculation, the health products of raising quality of life.Invention further provides composition for including momordica grosvenori alcohol derivatives monomer (4) and application thereof.Momordica grosvenori alcohol derivatives monomer (4) has the high antitumor validity of wide spectrum, its activity and validity are superior to tetracyclic triterpene glucoside antitumor medicine/health products Rg3 similar with its structure in the market, and its validity is also above broad-spectrum anti-cancer drug taxol, it can be made for treating and/or prevent various cancers and/or the medicine of tumour, and for immunological regulation and/or improve the health products of microcirculation and/or raising quality of life, emphasis is applied to the treatment of malignant tumour, has broad application prospects.
Description
Technical field
The present invention relates to field of medicaments, and in particular to a kind of purposes of momordica grosvenori alcohol derivatives monomer and combinations thereof.
Background technology
Cancer is the second-biggest-in-the-world disease for torturing human life, and the death rate is only second to cardiovascular and cerebrovascular disease, is that the mankind are dead
One of main factor died.The IARC of cancer mechanism of official (IARC) for organizing subordinate by World Health Organization bears
The latest edition of duty《World's cancer report》Swift and violent propagation situation will be presented in prediction, global cases of cancer, by 2012 14,000,000
People, fast 19,000,000 people for increasing to 2025,24,000,000 people were up to by 2035 year by year.Report also shows that the whole world was new in 2012
Increasing cases of cancer has nearly half to appear in Asia, and wherein most is in China, and the newly-increased cases of cancer height of China ranks first.2012
Newly-increased 3,070,000 cancer patients of China simultaneously cause about 2,200,000 people death , Fen Do to account for the 21.9% and 26.8% of global total amount.WHO
Data be slightly below China statistics.2012 annual datas of national tumour Register issue show that China is annual newly-increased
Cases of cancer about 3,500,000, there are about 2,500,000 people therefore dead.
The common method for the treatment of of cancer mainly has Three models now：Operation, radiotherapy and drug therapy, and which is selected and controlled
Treatment method then depends on position, grade malignancy, development degree and the patient body state of tumour.In Three models, operation
Treatment method, the invasion of Chang Yinwei cancer cells spreads to adjacent tissue or far-end transfer and effect is limited；The treatment method of radiotherapy, then
It is limited to the injury caused to other internal normal structures；The treatment method of medicine, it is pernicious for late period dispersivity and metastatic
Tumour is most basic treatment method.In past decades, though being conceived to the chemotherapy of direct killing tumour cell has significantly
Development and progress, the backbone as tumor pharmacother, but this Therapeutic mode are poor to the slow solid tumor effect of propagation, medicine
The defect that selectivity is small, toxicity is more and serious turns into the important limiting factor in clinical treatment.After operation, radiation and chemotherapy
The 4th kind of pattern afterwards is the biological therapy of tumour, and it mainly passes through the effect of tumor host defense mechanism or biological agent
To adjust the biologically of body itself, so as to suppress or eliminate tumour；Although biological therapy is without too big toxic side effect,
Because technical requirements are tight, complex process, therefore price is high, and numerous cancer patients and family members are difficult to bear, and influence it to be controlled in cancer
The popularization in treatment field.
Due to there is above-mentioned various limitations, the research and development of natural antitumor medicine achieve increasing concern.It is natural anti-
Cancer drug either in suppression or killing tumor cell, adjustment body's immunity, improvement symptom and feature and mitigates chemicotherapy
In toxic side effect, or in the conditioning after being ill of tumour, it is respectively provided with important function.Thus, natural plants new treatment will turn into after
The 5th kind of pattern after operation, radiotherapy, chemotherapy and biotherapy.
Momordica grosvenori is a kind of rare medicinal herbs, belongs to the perennial liana of Curcurbitaceae, cool in nature sweet.In Fructus Monordicae extract
The saponin constituent of the sweet taste containing non-saccharide, also known as momorside, the number and connection position of glycosyl are connected according to wherein sapogenin
Different separated in momorside put identifies Momordica grosvenori bioside, three glucosides, four glucosides, five glucosides, six sugar
A variety of saponin monomers such as glycosides, are respectively designated as mogroside II, III, IV, V, VI (MogrosideII, III, IV, V, VI)
Deng wherein momordica glycoside V-Mogroside V (1A) (as shown in Figure 1) sugariness is 256-344 times of sucrose, sweet Momordica grosvenori
Glycosides IV-Mogroside IV (1B) (as shown in Figure 1) sugariness is 126 times of sucrose, and its heat is zero, with clearing heat and moistening lung town
Obesity, constipation, diabetes etc. are had preventive and therapeutic effect by the effect of coughing, relax bowel.
Triterpene glucoside Mogrosides be two glucoside side chains being made up of less than four glucose units with β-
Glycosidic bond is connected with sapogenin momordica grosvenori alcohol Mogrol (2) (as shown in Figure 2) C-3, C-24, the company between pendant glucose
Key is connect for β -1,6 and β-l, 2 glycosidic bonds.
Many studies have shown that, triterpene glucoside can improve the utilization of glucose and fat, increase the sensitiveness of insulin, but
The active ingredient and mechanism of action of Momordica grosvenori hypoglycemic effect are simultaneously indefinite.Hu Lihong seminars of Shanghai institute of materia medica of the Chinese Academy of Sciences
The hypoglycemic effect of Momordica grosvenori is studied with Shen Xu seminars, first in HepG2 cells, to content in Momordica grosvenori most
High momordica glycoside V (1A) is tested, and finds it to AMPK without activity；And momordica grosvenori alcohol Mogrol (2) and its derivative
The alpha-hydroxy-2 5- dehydroxylations-24- ketone of thing 3-momordica grosvenori alcohol (3 α-hydroxy-25-dehydroxy-24-oxomogrol) (3)
(as shown in Figure 3) can but activate AMPK (Chen X.B., et al；Bioorganic&Medicinal Chemistry
2011,19:5776).At present, sieve is also generated by momordica grosvenori alcohol (2) under given conditions without any patent and document report
Chinese fruit 01 derivatives monomer (3) and momordica grosvenori alcohol derivatives monomer (4) (as shown in Figure 4), also without any patent and document report
Road there are momordica grosvenori alcohol derivatives monomer (4) with and application thereof.
The content of the invention
The technical problem to be solved in the present invention is to provide a kind of new application of momordica grosvenori alcohol derivatives monomer (4), the present invention
Further provide the new application for the composition for including momordica grosvenori alcohol derivatives monomer (4).
The following structure that the present invention is provided
Momordica grosvenori alcohol derivatives monomer (4), and in other most cucurbitaceous plants directly extract separation high oxidation calabash
Reed alkanes tetracyclic triterpenoids compound is different, and momordica grosvenori alcohol derivatives monomer (4) is protoxydic cucurbit alkanes tetracyclic triterpene chemical combination
Thing, that be characterized in connecting on C-3 and C-11 is-OH, rather than=O, and degree of oxidation lowers significantly, at present can not be directly from sieve
Extracting and developing in Chinese fruit platymiscium, it is difficult to prepare.
First aspect present invention provides following structure
One purposes of momordica grosvenori alcohol derivatives monomer (4), show preparation for treat and/or pre- preventing tumor and/or
Purposes in the medicine of cancer.
In a preference, wherein described tumour and/or cancer is selected from：
Malignant tumour, including carcinoma of urinary bladder, breast cancer, colon cancer, kidney, liver cancer, lung cancer, head and neck cancer, the cancer of the esophagus, gall-bladder
Cancer, oophoroma, cancer of pancreas, stomach cancer, cervix cancer, thyroid cancer, prostate cancer and cutaneum carcinoma, B- cell lymphoms, T- cells
Lymph cancer, Huo Qijin lymph cancers, non-Huo Qijin lymph cancers, hairy cell lymphom, teratocarcinoma, thyroid gland filter capsule cancer；
The hematopoetic tumor of lymphatic system, including leukaemia, mantle cell lymphoma, myeloma；
The hematopoetic tumor of marrow system, including acute and chronic myelocytic leukemia, myelodysplastic syndrome and
Promyelocytic leukemia；
The tumour of the interstitial origin cause of formation, including fibrosarcoma and rhabdomyosarcoma；
The tumour of maincenter and peripheral nervous system, including astrocytoma, into fibroneuroma, glioma and nerve
Sheath knurl；And
Other tumours, including melanoma, seminoma, osteosarcoma, exophytic pigment neck knurl and Kaposi's sarcoma.
Second aspect of the present invention provides following structure
Momordica grosvenori alcohol derivatives monomer (4) another purposes, show preparation for immunological regulation and/or improve it is micro-
Purposes in the health products of circulation and/or raising quality of life.
Third aspect present invention provides a purposes of the composition comprising above-mentioned momordica grosvenori alcohol derivatives monomer (4),
Show the purposes prepared in treatment and/or pre- preventing tumor and/or the medicine of cancer；In a preference, described is swollen
Knurl and/or cancer are selected from：
Malignant tumour, including carcinoma of urinary bladder, breast cancer, colon cancer, kidney, liver cancer, lung cancer, head and neck cancer, the cancer of the esophagus, gall-bladder
Cancer, oophoroma, cancer of pancreas, stomach cancer, cervix cancer, thyroid cancer, B- cell lymphoms, T- cell lymphoms, Huo Qijin lymphs
Cancer, non-Huo Qijin lymph cancers, hairy cell lymphom, teratocarcinoma, thyroid gland filter capsule cancer, prostate cancer and cutaneum carcinoma,；
The hematopoetic tumor of lymphatic system, including leukaemia, mantle cell lymphoma and myeloma；
The hematopoetic tumor of marrow system, including acute and chronic myelocytic leukemia, myelodysplastic syndrome and
Promyelocytic leukemia；
The tumour of the interstitial origin cause of formation, including fibrosarcoma and rhabdomyosarcoma；
The tumour of maincenter and peripheral nervous system, including astrocytoma, into fibroneuroma, glioma and nerve
Sheath knurl；And
Other tumours, including melanoma, seminoma, osteosarcoma, exophytic pigment neck knurl and Kaposi's sarcoma.
In a preference, the composition is pharmaceutical preparation, its described arhat comprising treatment and/or prevention effective dose
Fruit 01 derivatives monomer (4) and optional pharmaceutically acceptable diluent, auxiliary material or medium.
In a preference, the formulation of the pharmaceutical preparation is in peroral dosage form, injection type or Topical application forms
It is any；
In a preference, the peroral dosage form includes tablet, pulvis, suspension, emulsion, capsule, granule, sugar-coat
Piece, pill, spirit, syrup or limonada；
In a preference, the injection type includes suspension or solution；
In a preference, the Topical application forms include ointment, solid, suspension, spirit, pulvis, paste, bolt
Agent, aerosol, opoultice, liniment, lotion, enema or emulsion.Fourth aspect present invention provides and includes above-mentioned Momordica grosvenori
There is provided the combination for including above-mentioned momordica grosvenori alcohol derivatives monomer (4) for another purposes of the composition of 01 derivatives monomer (4)
One purposes of thing,
The composition is a kind of health products, its described momordica grosvenori alcohol derivative comprising treatment and/or prevention effective dose
Acceptable carrier in monomer (4) and optional health products.
Terminology used in the present invention have it is defined below, unless otherwise described：
Term " momordica grosvenori alcohol derivatives monomer (3) " used herein means 3 alpha-hydroxy-2 5- dehydroxylations -24- ketone-arhat
Fruit alcohol (3 α-hydroxy-25-Dehydroxy-24-oxomogrol) (structural formula is as shown in Figure 3)；Term " sieve used herein
Chinese fruit 01 derivatives monomer (4) " means 3 alpha-hydroxy-2s 2,24- diene -24,25- dehydroxylations-momordica grosvenori alcohol (3 α-hydroxy-
22nd, 24-diene-24,25-dehydroxy-mogrol) (4) (structural formula is as shown in Figure 4).
Term " composition " used herein means to include the product of each specified composition comprising specified amount, and directly or
Any product produced indirectly from the combination of each specified composition of specified amount.The Topical application forms include ointment, solid, hanged
Turbid liquid, aqua, spirit, pulvis, paste, suppository, aerosol, opoultice, liniment, lotion, enema or emulsion.In sterile bar
By reactive compound and pharmaceutically acceptable carrier and any required preservative, buffer or propellants under part.It is ophthalmically acceptable
Preparation, eye ointment, powder and solution are contemplated within the scope of the present invention.
When for above-mentioned treatment or other treatment, a kind of the compounds of this invention for the treatment of and/or prevention effective dose can be with
Apply in a pure form, or with pharmaceutically acceptable salt, ester or prodrug forms (in the case where there are these forms) application.Or
Person, the compound can be with the pharmaceutical composition containing the purpose compound Yu one or more pharmaceutically acceptable excipient
Administration.The compounds of this invention of word " treatment and/or prevention effective dose " refer to the reasonable effect suitable for any therapeutic treatment/
The compound of the sufficient amount of Hazard ratio treatment obstacle.It is to be understood that total consumption per day of the compounds of this invention and composition must be by
Attending physician makes decision in reliable medical judgment scope.For any specific patient, specific treatment and/or prevention
Depending on effective dose level must be according to many factors, the factor includes treated obstacle and the order of severity of the obstacle；Institute
The activity of the particular compound of use；The concrete composition used；Age of patient, body weight, general health, sex and
Diet；Administration time, method of administration and the excretion rate of the particular compound used；Treat the duration；With the tool used
Body compound is applied in combination or medicine used at the same time；And similar factor known to medical field.For example, the way of this area
It is that the dosage of compound is since the level required less than therapeutic effect needed for obtaining, gradually incremental dose, until obtaining
Required effect.
The present invention also provide comprising optionally with the acceptable diluent of one or more non-toxic pharmaceuticals, carrier, excipient,
The pharmaceutical preparation of auxiliary material or medium the compounds of this invention formulated together.The pharmaceutical preparation can especially particular formulation into
Solid or liquid form are for oral administration, for parental injection or supply rectally.
The present invention pharmaceutical composition can by oral, rectum, parenteral, pond, intravaginal, intraperitoneal, part (as lead to
Cross powder, ointment or drops), buccal gives the mankind and other mammals, or is used as oral spray or nasal spray
Agent is given.Terms used herein " parenteral " refer to including in intravenous, intramuscular, intraperitoneal, breastbone, subcutaneous and intra-articular injection
With the administering mode of transfusion.
In another aspect, the present invention provides the pharmaceutical composition comprising present component and physiologically tolerable diluent.
The present invention includes one or more above-claimed cpds, its nontoxic physiologically tolerable with one or more or acceptable diluent,
Carrier, auxiliary material or medium (they are referred to as into diluent herein) are configured to composition together, for parental injection, intranasal
Transmit, with solid or liquid form oral administration, rectum or local administration etc..
Being suitable for the composition of parental injection may include physiologically acceptable sterile, aqueous or non-aqueous liquor, disperses
Agent, supensoid agent or emulsion, and for being reconstructed into the sterile powders of Sterile injectable solution or dispersant.It is suitable aqueous or non-aqueous
Carrier, diluent, the example of solvent or medium include water, ethanol, polyalcohol (propane diols, polyethylene glycol, glycerine etc.), plant
Oily (such as olive oil), injectable organic ester such as ethyl oleate and their suitable mixture.
These compositions can also contain auxiliary material, such as preservative, wetting agent, emulsifying agent and dispersant.Pass through various antibacteriums
Agent and antifungal agent, such as parabens, anesin, phenol, sorbic acid, it can be ensured that prevent the effect of microorganism.
It is also expected to including isotonic agent, such as carbohydrate, sodium chloride.By using can postpone absorb material, for example aluminum monostearate and
Gelatin, the extension that can reach injectable drug form absorbs.
Suspending agent, such as ethoxylation i-octadecanol, polyoxyethylene mountain can also be contained in supensoid agent in addition to the active compound
Pears alcohol and polyoxyethylene sorbitan esters, microcrystalline cellulose, inclined aluminium hydroxide, bentonite, agar and bassora gum or this
Mixture of a little materials etc..
In some cases, it is the effect of extension medicine, expects to slow down the absorption for subcutaneously or intramuscularly injecting medicine.This can lead to
Cross using the crystal of poorly water-soluble or the liquid suspension of amorphous substance to realize.So, the infiltration rate of medicine is depended on
Its dissolution velocity, and dissolution velocity may depend on crystal size and crystal formation.Or, the delay of the medicament forms of parenteral
Absorption is realized by the way that the medicine to be dissolved in or be suspended in oily medium.
Injectable depot formulations form can be by biodegradable polymer such as polylactide-polyglycolide
(polylactide-polyglycolide) microcapsule matrix of medicine is formed in prepare.Can according to medicine and polymer it
Than the property with the specific polymer used, drug releasing rate is controlled by.The reality of other biological degradable polymer
Example includes poe class (poly (orthoesters)) and polyanhydrides (poly (anhydrides)).Injectable depot formulations
Also it can be prepared by the way that medicine is embedded in liposome or micro emulsion that can be compatible with bodily tissue.
Injectable formulation can be for example by using bacteria filter filtering or the bactericidal agent by mixing aseptic solid composite form
To sterilize, the solid composite can be dissolved or dispersed in sterilized water or other sterile injectable mediums before use.
Solid dosage forms for oral administration includes capsule, tablet, pill, powder and granule.In such solid dosage forms
In, reactive compound can be with least one inert pharmaceutically acceptable excipient or carrier such as sodium citrate or Dicalcium Phosphate
And/or following material mixing：A) filler or extender such as starch, lactose, sucrose, glucose, mannitol and silicic acid；B) glue
Mixture such as carboxymethyl cellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose and gum arabic；C) NMF is for example sweet
Oil；D) disintegrant such as agar, calcium carbonate, potato or tapioca, alginic acid, some silicate and sodium carbonate；E) solution hinders
Stagnant dose such as paraffin；F) absorbsion accelerator such as quaternary ammonium compound；G) wetting agent such as cetanol and glyceryl monostearate；H) adsorbent
Such as kaolin and bentonite and i) lubricant such as talcum powder, calcium stearate, magnesium stearate, solid polyethylene glycol, dodecyl
Sodium sulphate and their mixture.In the case of capsule, tablet and pill, buffer can be also included in the formulation.
The solid composite of similar type is using excipient such as lactose and high molecular weight polyethylene glycol, it is also possible to make soft
Filler in capsule and hard shell capsules.
Tablet, dragee (dragees), capsule, pill and granule solid dosage forms can be coated and shell material such as
Other clothing materials known to enteric coating material and field of medicine preparations are prepared together.These solid dosage forms can optionally contain opacifier, and
Its constitute can also make its be or preferentially enteron aisle some position optionally with delayed mode discharge active component.It can use
Embedding composition example include polymer substance and wax class.If be adapted to, reactive compound also can with one or more
State excipient and be made into microencapsulated form.
Liquid dosage form for oral administration includes pharmaceutically acceptable emulsion, solution, supensoid agent, syrup and elixir.
Liquid dosage form is removed can also contain inert diluent commonly used in the art containing active ingredient beyond the region of objective existence, and such as water or other solvents increase
Solvent and emulsifying agent such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzylalcohol, Ergol, propane diols, 1,3- fourths two
Alcohol, dimethylformamide, oils (are particularly cottonseed oil, peanut oil, corn oil, embryo oil, olive oil, castor oil and sesame
Oil), glycerine, tetrahydrofurfuryl alcohol (tetrahydrofurfuryl alcohol), the aliphatic acid of polyethylene glycol and sorbitan
Ester and their mixture.Orally administered composition can also include auxiliary material in addition to comprising inert diluent, such as wetting agent, emulsification and outstanding
Floating agent, sweetener, flavouring and flavouring agent.
Suppository is preferably for the composition of rectum or vagina administration.Suppository can by by the compounds of this invention with it is suitable non-
Excitant excipient or carrier such as cocoa butter, polyethylene glycol or suppository wax mix to prepare, and they are solid at room temperature, but
It is then under body temperature liquid, therefore can be melted in rectal cavity or vaginal canal and discharge reactive compound.
The compounds of this invention can also liposomal form administration.As it is known in the art, liposome generally with phosphatide or its
He is made lipid material.Liposome is formed by the single or multiple lift aquation liquid crystal being scattered in water-bearing media.It is any being capable of shape
Into liposome it is nontoxic, be physiologically subjected to and metabolizable lipid can be used.The present composition of liposomal form is removed
Outside containing the compounds of this invention, it can also contain stabilizer, preservative, excipient etc..It is preferred that lipid be natural and synthesis phosphorus
Fat and phosphatidyl choline (lecithin), they can be used individually or together.The method for forming liposome is well known in the art.
Term " pharmaceutically acceptable prodrug " used herein represents the prodrug of the compounds of this invention, and it is in reliable medical science
It is suitable for contacting with the tissue of the mankind and lower animal in determination range and occurs without excessive toxicity, stimulation, allergic reaction
Deng, match with rational effect/Hazard ratio and to its intended purpose effectively, the compounds of this invention is also represented in the conceived case
Zwitterionic form.The present invention prodrug can for example by hydrolyzing and being rapidly converted into vivo in blood above formula parent
Compound.
Momordica grosvenori alcohol derivatives monomer (4) in the present invention, which has, suppresses human tumor cells (23 kinds have been surveyed cancer cell) and people
The antitumor activity of huve cell propagation, can be made for treating and/or prevent various cancers and/or tumour
Medicine, and for immunological regulation and/or improve the health products of microcirculation and/or raising quality of life, emphasis is applied to pernicious
The treatment of tumour, has broad application prospects.
Brief description of the drawings
Fig. 1 is momordica glycoside V (1A), VI (1B) schematic arrangement.
Fig. 2 is momordica grosvenori alcohol Mogrol (2) schematic arrangement.
Fig. 3 is the schematic arrangement of momordica grosvenori alcohol derivatives monomer (3).
Fig. 4 is the schematic arrangement of momordica grosvenori alcohol derivatives monomer (4).
Embodiment
Unless specifically indicated, term used herein has the general sense in art of the present invention.
Below with reference to specific embodiment, the present invention will be described, it is necessary to which explanation, these embodiments are only explanation
Property, and be not considered as limiting the invention.Unreceipted particular technique or condition in embodiment, according in the art
Technology or condition described by document are carried out according to product description.Agents useful for same or the unreceipted production firm person of instrument,
Being can be by the conventional products of acquisition purchased in market.
Embodiment 1：Momordica grosvenori alcohol derivatives monomer (3) and (4) are prepared from the extract of momorside 98%
By Fructus Monordicae extract 50g, (momorside 98%, containing 55% mogroside V, buys biological in Guilin Rhein
Science and Technology Co., Ltd.) add 250mL ethanol the aqueous solution (volume ratio of second alcohol and water be 1:1) (adjusted in advance with hydrochloric acid
Section is to pH value for 3.0), stirring and dissolving, then heats at 120 DEG C and heat 2 hours, be cooled to 25 DEG C of room temperature in a kettle.
Afterwards, it is 7 that reaction solution, which is neutralized to pH value with 1M NaOH alkali lye, and ethanol is tried one's best at 90-95 DEG C and steamed, remaining concentrate adds
Enter 200mL distilled water, cool down, stand after being sufficiently stirred for, water layer separation above is discarded, coffee-like medicinal extract is obtained；Use respectively
The coffee-like medicinal extract of 100mL, 50mL, 50mL ethyl acetate extraction 3 times, merges after 3 extracts, with rotation at 100-120 DEG C
Evaporimeter is concentrated, and ethyl acetate is evaporated completely, that is, obtains derivatives monomer containing momordica grosvenori alcohol (3) and momordica grosvenori alcohol derivative list
The light coffee color solid 18.2g of body (4)；Light coffee color solid is loaded into silicagel column with ethanol, acetonitrile is used：Water (volume ratio 20:1)
Gradient elution, sequentially collects and A (6.8g), the components of B (5.6g) two is obtained after different effluxes, concentration；First collect
A (6.8g) component arrived uses silica gel post separation (chloroform again：Ethanol/60:5 elutions), obtain momordica grosvenori alcohol derivatives monomer (3)
4.1g(HPLC>99%).ESIMS m/z503(458+45)[M+HCOO-]-(calcd for C31H51O5)；13C-NMR
(600MHz, MeOD) δ ppm:29.1(C-1),31.7(C-2),79.4(C-3),42.8(C-4),144.1(C-5),120.7(C-
6),25.2(C-7),44.8(C-8),41.1(C-9),35.4(C-10),77.7(C-11),30.6(C-12),48.3(C-13),
49.6(C-14),34.9(C-15),27.5(C-16),50.7(C-17),17.2(C-18),26.6(C-19),41.1(C-20),
19.0(C-21),37.8(C-22),40.3(C-23),218.2(C-24),35.4(C-25),18.8(C-26),18.8(C-
27),26.4(C-28),19.9(C-29),19.3(C-30)；With 3a- hydroxyl -25- dehydroxylations -24- carbonyls-sieve of document report
Chinese fruit alcohol (3a-hydroxy-25-Dehydroxy-24-oxomogrol) carbon modal data compares, the two basically identical (Chen
X.B., et al；Bioorganic&Medicinal Chemistry 2011,19:5776).
Obtained B (5.6g) component is collected afterwards uses silica gel post separation (petroleum ether again：Ethyl acetate/5:2 elutions), obtain sieve
Chinese fruit 01 derivatives monomer (4).3.2g(HPLC>99%).ESIMS m/z441[M+H]+(calcd for C30H49O2)；13C-
NMR (600MHz, MeOD) δ ppm:23.5(C-1),29.5(C-2),87.8(C-3),44.2(C-4),144.1(C-5),121.8
(C-6),25.5(C-7),40.9(C-8),40.8(C-9),51.3(C-10),71.9(C-11),41.5(C-12),48.2(C-
13),52.2(C-14),35.3(C-15),24.9(C-16),54.3(C-17),15.2(C-18),18.6(C-19),40.2(C-
20),20.3(C-21),137.4(C-22),128.8(C-23),125.4(C-24),143.3(C-25),19.7(C-26),
25.7(C-27),21.7(C-28),21.7(C-29),18.6(C-30)。
Embodiment 2：Momordica grosvenori alcohol derivatives monomer (3) and (4) are prepared from the extract of momorside 95%
By Fructus Monordicae extract 50g (momorsides 95%, containing 45% mogroside V, from Guilin Rhein biotechnology
Limited company buy) add 250mL methanol the aqueous solution (volume ratio of first alcohol and water be 3:2) (adjusted in advance with sulfuric acid
Section is to pH value for 2.8), stirring and dissolving, then heats at 120 DEG C and heat 2 hours, be cooled to after room temperature, instead in a kettle.
It is 7 to answer liquid to be neutralized to pH value with 1M KOH alkali lye, and methanol is tried one's best at 90-95 DEG C and steamed, remaining concentrate is added
200mL distilled water, is cooled down after being sufficiently stirred for, stands, and water layer separation above is discarded, coffee-like medicinal extract is obtained；Use respectively
The coffee-like medicinal extract of 100mL, 50mL, 50mL ethyl acetate extraction 3 times, merges after 3 extracts, with rotation at 100-120 DEG C
Evaporimeter is concentrated, and ethyl acetate is evaporated completely, that is, obtains derivatives monomer containing momordica grosvenori alcohol (3) and momordica grosvenori alcohol derivative list
The light coffee color solid 15.5g of body (4)；Light coffee color solid is loaded into silicagel column with methanol, acetonitrile is used：Water (19:1) gradient is washed
It is de-, sequentially collect and A (6.0g), the components of B (5.2g) two are obtained after different effluxes, concentration；First collect obtained A
(6.0g) component uses silica gel post separation (chloroform again：Ethanol/60:5 elutions), obtain momordica grosvenori alcohol derivatives monomer (3) 3.9g
(HPLC>99%)；HPLC、13C-NMR, ESIMS testing result are consistent with the compound (3) in embodiment 1.Obtained B is collected afterwards
(5.2g) component uses silica gel post separation (petroleum ether again：Ethyl acetate/3:1 elution), obtain momordica grosvenori alcohol derivatives monomer (4).
3.0g(HPLC>99%)；HPLC、13Momordica grosvenori alcohol derivatives monomer (4) one in C-NMR, ESIMS testing result and embodiment 1
Cause.
Embodiment 3：Momordica grosvenori alcohol derivatives monomer (3) and (4) are prepared from the extract of momorside 90%
By Fructus Monordicae extract 50g (momorsides 90%, containing 40% mogroside V, from Guilin Rhein biotechnology
Limited company buy) add 250mL normal propyl alcohol the aqueous solution (volume ratio of normal propyl alcohol and water be 2:3) (first is used in advance
Acid regulation to pH value is 3.2, in a kettle. stirring and dissolving, then heats at 120 DEG C and heats 2 hours, is cooled to after room temperature,
It is 7 that reaction solution, which is neutralized to pH value with 1M NaOH alkali lye, and normal propyl alcohol is tried one's best at 90-95 DEG C and steamed, remaining concentrate adds
Enter 200mL distilled water, cool down, stand after being sufficiently stirred for, water layer separation above is discarded, coffee-like medicinal extract is obtained；Use respectively
The coffee-like medicinal extract of 100mL, 50mL, 50mL ethyl acetate extraction 3 times, merges after 3 extracts, with rotation at 100-120 DEG C
Evaporimeter is concentrated, and ethyl acetate is evaporated completely, that is, obtains derivatives monomer containing momordica grosvenori alcohol (3) and momordica grosvenori alcohol derivative list
The light coffee color solid 14.2g of body (4)；Light coffee color solid is loaded into silicagel column with methanol/ethanol, acetonitrile is used：Water (20:1)
Gradient elution, sequentially collects and A (5.4g), the components of B (4.3g) two is obtained after different effluxes, concentration；First collect
A (5.4g) component arrived uses silica gel post separation (chloroform again：Ethanol/60:5 elutions), obtain momordica grosvenori alcohol derivatives monomer (3)
3.5g(HPLC>99%)；HPLC、13C-NMR, ESIMS testing result are consistent with the compound (3) in embodiment 1.After collect
B (4.3g) component arrived uses silica gel post separation (petroleum ether again：Ethyl acetate/6:4 elutions), obtain momordica grosvenori alcohol derivatives monomer
(4)2.8g(HPLC>99%)；HPLC、13Momordica grosvenori alcohol derivatives monomer in C-NMR, ESIMS testing result and embodiment 1
(4) it is consistent.
Embodiment 4：Momordica grosvenori alcohol derivatives monomer (3) and (4) are prepared from the extract of momorside 80%
By Fructus Monordicae extract 50g (momorsides 80%, containing 20% mogroside V, from Guilin Rhein biotechnology
Limited company buy) add 250mL ethanol the aqueous solution (volume ratio of second alcohol and water be 1:1) (ethanedioic acid is used in advance
Regulation to pH value is that 2.6), stirring and dissolving, then heats at 120 DEG C and heat 2 hours, be cooled to after room temperature in a kettle.,
Reaction solution 1M Na2CO3It is 7 that alkali lye, which is neutralized to pH value, and ethanol is tried one's best at 90-95 DEG C and steamed, and remaining concentrate is added
200mL distilled water, is cooled down after being sufficiently stirred for, stands, and water layer separation above is discarded, coffee-like medicinal extract is obtained；Use respectively
The coffee-like medicinal extract of 100mL, 50mL, 50mL ethyl acetate extraction 3 times, merges after 3 extracts, with rotation at 100-120 DEG C
Evaporimeter is concentrated, and ethyl acetate is evaporated completely, that is, obtains derivatives monomer containing momordica grosvenori alcohol (3) and momordica grosvenori alcohol derivative list
The light coffee color solid 8.8g of body (4)；Light coffee color solid is loaded into silicagel column with methanol/ethanol, acetonitrile is used：Water (95:5) it is terraced
Degree elution, sequentially collects and A (3.8g), the components of B (3.0g) two is obtained after different effluxes, concentration；First collect and obtain
A (3.8g) component again use silica gel post separation (chloroform：Ethanol/60:5 elutions), obtain momordica grosvenori alcohol derivatives monomer (3) 2.1g
(HPLC>99%)；HPLC、13C-NMR, ESIMS testing result are consistent with the compound (3) in embodiment 1.Obtained B is collected afterwards
(3.0g) component uses silica gel post separation (petroleum ether again：Ethyl acetate/4:1 elution), obtain momordica grosvenori alcohol derivatives monomer (4)
1.8g(HPLC>99%)；HPLC、13Momordica grosvenori alcohol derivatives monomer (4) one in C-NMR, ESIMS testing result and embodiment 1
Cause.
Embodiment 5：Momordica grosvenori alcohol derivatives monomer (4) suppresses cell proliferation experiment
Laboratory sample：
Testing drug：The momordica grosvenori alcohol derivatives monomer (4) that embodiment 1 is prepared；
Control drug：Taxol (SELLECK；Cat.#S1150)；Ginsenoside monomer Rg3 is (from the biological section of Shanghai source leaf
Skill Co., Ltd buys, and commodity article No. is B21059).
Experimental procedure：
With 24 kinds of cell lines (including 23 kinds of tumor cell lines and a kind of human umbilical vein endothelial cell line) for experiment cell
System, take the logarithm growth period cell (3x 104/ mL to 2.5x 105/ mL), it is seeded in every μ L of hole 100 in 96 orifice plates, each cell
It is with 96 orifice plates；Then, in addition to control drug taxol, 7 logarithms are taken to pass for 2 μM to low concentration with 150 μM of high concentration
Subtract concentration (each concentration sets two multiple holes), being separately added into testing drug solution and control drug solution 500nL, (testing drug is molten
Liquid or control drug solution are prepared：Be respectively adopted testing drug or control drug be dissolved in 0.5% DMSO solution).Taxol
It is by 7 three times decreasing concentrations of 1 μM of high concentration to 0.0014 μM of low concentration to add concentration.After tested/control drug solution is made
After 72 hours, use(Promega；Cat.#G7573) luminescent cell viability examination method obtains each cell line
In each concentration of every kind of medicine be the Proliferation Ability percentage of cell to this, and dose-effect relationship figure is drawn, finally according to figure
Middle curve calculates IC50Suppress percentage (E with highestmax), as shown in Table 1 and Table 2.
Table 1：Momordica grosvenori alcohol derivatives monomer (4) and comparison medicine Rg3 suppress cell-proliferation activity laboratory test results.
Table 2：Momordica grosvenori alcohol derivatives monomer (4) and comparison medicine taxol, Rg3 suppress the experiment inspection of cell propagation efficacy
Survey result.
Use SPSS Statistics software (suppliers：IBM corporation, software version:XL fit 21) carry
For statistical analysis.
Medicine group is detected with the unequal independent sample inspection (independent-sample T-test) of variance is assumed
Statistically significant (P whether is presented with the difference for compareing cell mean<0.05 or P<0.01).
Analysis result：
1. average IC50 of the momordica grosvenori alcohol derivatives monomer (4) of the present invention in 24 cell line and control drug ginseng soap
When average IC50s of the glycosides monomer Rg3 in 24 cell line compares, statistically significant (P is presented in difference<0.05 while P<0.01).
2. average highest of the momordica grosvenori alcohol derivatives monomer (4) of the present invention in 24 cell line suppresses percentage with compareing
The average highest of drug taxol and control drug ginsenoside monomer Rg3 in 24 cell line suppresses percentage comparisons
When, statistically significant (P is presented in difference<0.05 while P<0.01).
Conclusion：
1. momordica grosvenori alcohol derivatives monomer (4) of the present invention is in all 24 kinds suppression cell-proliferation activities surveyed in cell line
It is above the similar control drug ginsenoside monomer Rg3 (IC of momordica grosvenori alcohol derivatives monomer (4)50Less than ginsenoside monomer
Rg3 IC50)。
2. in all tested cell systems, momordica grosvenori alcohol derivatives monomer (4) of the present invention is in people's bleeding of the umbilicus venous endothelial cell
It is there is highest to suppress cell-proliferation activity (IC in HUVEC50=10.72 μM), show its powerful Antineoplastic angiogenesis
Potentiality；Momordica grosvenori alcohol derivatives monomer (3) suppresses cell-proliferation activity in Colon and rectum gland cancer cell line HCT-8 and comes next
(IC50=14.83 μM).
3. momordica grosvenori alcohol derivatives monomer (4) of the present invention is to the highest inhibiting rate (validity) of all 24 kinds of tested cell systems
All closely 100%；And comparison medicine taxol and ginsenoside monomer Rg3 be in the 24 kinds of cell lines surveyed, only to 2 kinds
Cell line has nearly 100% inhibiting rate.This shows the validity of momordica grosvenori alcohol derivatives monomer (4) apparently higher than control drug,
And its high anticancer validity is applied to multiclass cancer kind.
Claims (10)
1. with following structural formula：
Momordica grosvenori alcohol derivatives monomer (4) prepare for treat and/or pre- preventing tumor and/or the medicine of cancer in use
On the way.
2. purposes according to claim 1, it is characterised in that wherein described tumour and/or cancer is selected from：
Malignant tumour, selected from carcinoma of urinary bladder, breast cancer, colon cancer, kidney, liver cancer, lung cancer, head and neck cancer, the cancer of the esophagus, gallbladder cancer,
Oophoroma, cancer of pancreas, stomach cancer, cervix cancer, thyroid cancer, prostate cancer and cutaneum carcinoma, B- cell lymphoms, T- Lymphocytes
Cancer, Huo Qijin lymph cancers, non-Huo Qijin lymph cancers, hairy cell lymphom, teratocarcinoma, thyroid gland filter capsule cancer；
The hematopoetic tumor of lymphatic system, selected from leukaemia, mantle cell lymphoma, myeloma；
The hematopoetic tumor of marrow system, selected from acute and chronic myelocytic leukemia, myelodysplastic syndrome and preceding marrow
Cell leukemia；
The tumour of the interstitial origin cause of formation, selected from fibrosarcoma and rhabdomyosarcoma；
The tumour of maincenter and peripheral nervous system, selected from astrocytoma, into fibroneuroma, glioma and neurolemma
Knurl；And
Other tumours, selected from melanoma, seminoma, osteosarcoma, exophytic pigment neck knurl and Kaposi's sarcoma.
3. with following structural formula：
Momordica grosvenori alcohol derivatives monomer (4) prepare for immunological regulation and/or improve microcirculation and/or improve quality of life
Health products in purposes.
4. including following structural formula：
Momordica grosvenori alcohol derivatives monomer (4) composition prepare treatment and/or pre- preventing tumor and/or the medicine of cancer in
Purposes.
5. purposes according to claim 4, it is characterised in that wherein described tumour and/or cancer is selected from：
Malignant tumour, selected from carcinoma of urinary bladder, breast cancer, colon cancer, kidney, liver cancer, lung cancer, head and neck cancer, the cancer of the esophagus, gallbladder cancer,
Oophoroma, cancer of pancreas, stomach cancer, cervix cancer, thyroid cancer, B- cell lymphoms, T- cell lymphoms, Huo Qijin lymph cancers,
Non- Huo Qijin lymph cancers, hairy cell lymphom, teratocarcinoma, thyroid gland filter capsule cancer, prostate cancer and cutaneum carcinoma；
The hematopoetic tumor of lymphatic system, selected from leukaemia, mantle cell lymphoma and myeloma；
The hematopoetic tumor of marrow system, selected from acute and chronic myelocytic leukemia, myelodysplastic syndrome and preceding marrow
Cell leukemia；
The tumour of the interstitial origin cause of formation, selected from fibrosarcoma and rhabdomyosarcoma；
The tumour of maincenter and peripheral nervous system, selected from astrocytoma, into fibroneuroma, glioma and neurolemma
Knurl；And
Other tumours, selected from melanoma, seminoma, osteosarcoma, exophytic pigment neck knurl and Kaposi's sarcoma.
6. purposes according to claim 5, it is characterised in that said composition is pharmaceutical preparation, it is comprising treatment and/or in advance
Momordica grosvenori alcohol derivatives monomer (4) described in the claim 1 of anti-effective dose and optional pharmaceutically acceptable diluent, auxiliary material
Or medium.
7. purposes according to claim 6, it is characterised in that the formulation of the pharmaceutical preparation is peroral dosage form, injection
Any one of type or Topical application forms.
8. purposes according to claim 7, it is characterised in that the peroral dosage form includes tablet, pulvis, suspension, breast
Turbid liquid, capsule, granule, sugar coated tablet, pill, spirit, syrup or limonada；
Optional, the injection type includes suspension or solution；
It is optional, the Topical application forms include ointment, suspension, spirit, pulvis, paste, suppository, aerosol, opoultice,
Liniment, lotion, enema or emulsion.
9. including following structural formula：
The composition of momordica grosvenori alcohol derivatives monomer (4) preparing for immunological regulation and/or improving microcirculation and/or raising
Purposes in the health products of quality of life.
10. the purposes according to claim 9, it is characterised in that said composition is health products, its comprising treatment and/or
Acceptable carrier in momordica grosvenori alcohol derivatives monomer (4) described in the claim 1 of prevention effective dose and optional health products.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2016/089203 WO2017190420A1 (en) | 2016-05-06 | 2016-07-07 | Uses of mogrol derivative monomer and composition thereof |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610298720 | 2016-05-06 | ||
| CN201610298720X | 2016-05-06 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106188205A CN106188205A (en) | 2016-12-07 |
| CN106188205B true CN106188205B (en) | 2017-08-25 |
Family
ID=57465217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610520359.0A Active CN106188205B (en) | 2016-05-06 | 2016-07-04 | A kind of purposes of momordica grosvenori alcohol derivatives monomer and combinations thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN106188205B (en) |
| WO (1) | WO2017190420A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105832748B (en) * | 2016-05-06 | 2019-06-07 | 深圳以诺生物制药有限公司 | A method of preparing momordica grosvenori alcohol derivative from momorside |
| CN105777837A (en) * | 2016-05-06 | 2016-07-20 | 深圳以诺生物制药有限公司 | Novel Mogrol derivative monomer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070032464A1 (en) * | 2004-10-08 | 2007-02-08 | Shutsung Liao | Methods of treating cancers |
| CN101033244B (en) * | 2007-04-05 | 2010-05-19 | 上海交通大学 | Purification and preparation method of grosvenorol |
| EP2459581A4 (en) * | 2009-07-29 | 2012-12-26 | Univ Chicago | LIVER X RECEPTOR AGONISTS |
| CN105451742B (en) * | 2013-01-07 | 2021-04-06 | 布莱阿姆青年大学 | Methods for reducing cell proliferation and treating certain diseases |
| US10286000B2 (en) * | 2013-10-25 | 2019-05-14 | St. Jude Children's Research Hospital, Inc. | Retinoid X receptor-gamma agonists and retinoid X receptor-alpha antagonists for treatment of cancer |
| CN105832748B (en) * | 2016-05-06 | 2019-06-07 | 深圳以诺生物制药有限公司 | A method of preparing momordica grosvenori alcohol derivative from momorside |
| CN105777837A (en) * | 2016-05-06 | 2016-07-20 | 深圳以诺生物制药有限公司 | Novel Mogrol derivative monomer |
-
2016
- 2016-07-04 CN CN201610520359.0A patent/CN106188205B/en active Active
- 2016-07-07 WO PCT/CN2016/089203 patent/WO2017190420A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| CN106188205A (en) | 2016-12-07 |
| WO2017190420A1 (en) | 2017-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101392015B (en) | Triterpene saponins in camellia seeds, preparation method and medicinal use thereof | |
| CN105769891B (en) | Low polarity rare ginsenoside mixture and application thereof | |
| CN102008475B (en) | Application of quinolizidine in preparing tumor treatment drugs | |
| CN104546883B (en) | Preparation and application of flavonols as brain targeting synergists | |
| CN104910240B (en) | Triterpene saponins in Bougainvillea glabra, hypoglycemic drug using it as an active ingredient, and preparation method and application thereof | |
| CN106083972B (en) | A kind of momordica grosvenori alcohol derivatives monomer | |
| CN102526146B (en) | Pharmaceutical composition containing ginsenoside and cantharidin and use thereof | |
| CN106220701B (en) | triterpene compound and preparation method and application thereof | |
| CN101781355B (en) | Method for preparing limonin, composition and application thereof | |
| CN102068535B (en) | Fructus Aurantii Immaturus or fructus Aurantii total flavone extract extracted by ethanol reflux and its application | |
| CN104707148A (en) | Polyethylene glycol modified glycyrrhetinic acid and curcumin compound used for resisting hepatic carcinoma, and preparation method thereof | |
| CN102516344B (en) | Compound with antitumor activity and preparation method and application thereof | |
| CN106188205B (en) | A kind of purposes of momordica grosvenori alcohol derivatives monomer and combinations thereof | |
| CN104622865A (en) | Application of ingenane diterpene compound in preparation of antitumor drug | |
| CN105963307B (en) | A kind of purposes of momordica grosvenori alcohol derivatives monomer and combinations thereof | |
| US20050287230A1 (en) | Method of producing ginsenoside 20 (R)-Rh2 and composition of matter thereof | |
| CN103893412B (en) | A kind of antitumor beautyberry extract and its production and use | |
| CN101284042B (en) | Glycyrrhiza extract for alleviating cardiotoxicity of medicine and application | |
| CN102688248A (en) | Use of bufadienolide compound in preparing medicines for treating oral mucosal malignant tumors | |
| CN102875615A (en) | Extraction method and application of falcate dolichos root or leaf glucoside A and total saponins of falcate dolichos root or leaf | |
| CN102048874B (en) | General flavone extractive of immature bitter orange or bitter orange extracted through water decoction and use of general flavone extractive | |
| CN102858359B (en) | Medicinal composition comprising alcohol-soluble and water-insoluble licorice extract, pharmaceutical preparation, pharmaceutical application, therapeutic method, and preparative method thereof | |
| CN101062040B (en) | Stable type cucurbitacin liquid formula and the agent thereof | |
| CN102204919B (en) | Application of bufotalin to preparation of medicament for treating intracranial tumors | |
| CN1944454B (en) | Anticancer compound, extraction method of compound, composition containing compound and application of compound in pharmacy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |